How is succinylcholine (SCh) metabolized in patients with muscular dystrophy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Succinylcholine Metabolism in Muscular Dystrophy

Succinylcholine is absolutely contraindicated in patients with muscular dystrophy—the question of metabolism speed is clinically irrelevant because the drug should never be administered to these patients due to the risk of immediate cardiac arrest from hyperkalemic crisis. 1, 2

Critical Safety Issue: Contraindication, Not Metabolism

The focus on metabolism speed misses the fundamental danger in muscular dystrophy patients:

  • Succinylcholine disrupts unstable cell membranes in dystrophic muscle, causing acute rhabdomyolysis and massive potassium release within minutes of injection 1
  • Cardiac arrest can occur within minutes of succinylcholine administration in patients with Duchenne muscular dystrophy or other muscular dystrophies 1, 3, 4
  • The mechanism is not related to prolonged drug action but rather to immediate membrane disruption and potassium efflux from damaged muscle cells 1

Pharmacokinetics in Normal vs. Dystrophic Patients

Normal Metabolism

  • In patients without muscular dystrophy, succinylcholine is rapidly hydrolyzed by plasma cholinesterase, with levels falling below detection (2 μg/mL) within 2.5 minutes after IV bolus 5
  • Duration of neuromuscular blockade is approximately 4-6 minutes in normal patients 5

The Problem in Muscular Dystrophy

  • The issue is NOT slower or faster metabolism—plasma cholinesterase activity is typically normal in muscular dystrophy patients 1
  • The catastrophic complication occurs because dystrophic muscle has upregulated nicotinic acetylcholine receptors across the entire muscle membrane surface, leading to massive potassium efflux when depolarized 1
  • This creates life-threatening hyperkalemia regardless of how quickly the drug is metabolized 1, 5

Clinical Presentation and Timing

The hyperkalemic cardiac arrest occurs immediately, not after prolonged exposure:

  • Cardiac arrest presents within minutes, often accompanied by lack of fasciculations, muscle rigidity, myoglobinuria, and massive elevation of serum creatine phosphokinase 4
  • Unlike chronic hyperkalemia, succinylcholine-induced hyperkalemia in myopathy patients presents with immediate cardiac arrest without warning—sudden severe arrhythmias including wide complex tachycardia, bradycardia progressing to asystole, or ventricular fibrillation 1
  • Asystole may be prolonged and refractory to treatment, often requiring 10-12 minutes of CPR with aggressive treatment including calcium, insulin/glucose, and hyperventilation 1, 3, 4

Absolute Contraindication

Succinylcholine is absolutely contraindicated in all forms of muscular dystrophy, including:

  • Duchenne muscular dystrophy 1, 2, 6
  • Becker muscular dystrophy 1, 3
  • All skeletal muscle myopathies 7, 1

Safe Alternative

Rocuronium at doses ≥0.9 mg/kg (preferably 1.0-1.2 mg/kg) is the recommended alternative for rapid sequence intubation in patients with known or suspected muscular dystrophy 1, 8, 2

  • Rocuronium has a longer duration of action (30-60 minutes) compared to succinylcholine, but this disadvantage is vastly outweighed by its superior safety profile 1, 8
  • Sugammadex should be immediately available for reversal if needed 8

Critical Pitfall to Avoid

Never assume normal metabolism means safety—the catastrophic complication in muscular dystrophy is independent of drug metabolism speed and occurs through a completely different mechanism (membrane disruption and rhabdomyolysis) than the drug's intended neuromuscular blocking effect 1, 4

References

Guideline

Succinylcholine Safety After Receptor Upregulation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Succinylcholine Contraindications and Safety Considerations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Succinylcholine Use and Side Effects

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.